Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer | Zendy

Alice T. Shaw | Zendy; DongWan Kim | Zendy; Kazuhiko Nakagawa | Zendy; Takashi Seto | Zendy; Lucio Crinó | Zendy; MyungJu Ahn | Zendy; Tommaso De Pas | Zendy; Benjamin Besse | Zendy; Benjamin Solomon | Zendy; Fiona Blackhall | Zendy; YiLong Wu | Zendy; Michael Thomas | Zendy; Kenneth J. O’Byrne | Zendy; Denis MoroSibilot | Zendy; D. Ross Camidge | Zendy; Tony Mok | Zendy; Vera Hirsh | Zendy; Gregory J. Riely | Zendy; Shrividya Iyer | Zendy; Vanessa Tassell | Zendy; Anna Polli | Zendy; Keith D. Wilner | Zendy; Pasi A. Jänne | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer

Author(s) -

Alice T. Shaw,

DongWan Kim,

Kazuhiko Nakagawa,

Takashi Seto,

Lucio Crinó,

MyungJu Ahn,

Tommaso De Pas,

Benjamin Besse,

Benjamin Solomon,

Fiona Blackhall,

YiLong Wu,

Michael Thomas,

Kenneth J. O’Byrne,

Denis MoroSibilot,

D. Ross Camidge,

Tony Mok,

Vera Hirsh,

Gregory J. Riely,

Shrividya Iyer,

Vanessa Tassell,

Anna Polli,

Keith D. Wilner,

Pasi A. Jänne

Publication year - 2013

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1214886

Subject(s) - crizotinib , medicine , ceritinib , lung cancer , alectinib , anaplastic lymphoma kinase , ros1 , oncology , chemotherapy , hazard ratio , docetaxel , chemotherapy regimen , pemetrexed , cancer , surgery , confidence interval , adenocarcinoma , malignant pleural effusion , cisplatin

In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK. Whether crizotinib is superior to standard chemotherapy with respect to efficacy is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research